Tumor-Specific Antigen Market, Global Outlook and Forecast 2022-2028

February 2022 | 62 pages | ID: T94DA8D4CC72EN
Market Monitor Global

Abstracts

Tumor-specific Antigen is a new Antigen that is expressed on the surface of certain Tumor cells but not on normal cells.Such antigens may be present in tumors of the same tissue type in different individuals.Tumor-specific antigens help the body develop an immune response to cancer cells.They could be used as potential targets for targeted therapy or immunotherapy to help improve the body's immune system to kill more cancer cells.Tumor-specific antigens can also be used in laboratory tests to help identify certain types of cancer.

This report contains market size and forecasts of Tumor-Specific Antigen in Global, including the following market information:

Global Tumor-Specific Antigen Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Tumor-Specific Antigen market was valued at 2204.1 million in 2021 and is projected to reach US$ 3142.3 million by 2028, at a CAGR of 5.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Coding Region Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor-Specific Antigen include Agilent Technologies, Creative Diagnostics, Go Therapeutics, Lee Biosolutions, Bio-Rad, Biomrieux, Caris Life Sciences, Roche and Abcam, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor-Specific Antigen companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor-Specific Antigen Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Tumor-Specific Antigen Market Segment Percentages, by Type, 2021 (%)

• Coding Region
• Non-Coding Region

Global Tumor-Specific Antigen Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Tumor-Specific Antigen Market Segment Percentages, by Application, 2021 (%)

• Drug Discovery and Development
• Diagnostics
• Clinical and Basic Research
• Others

Global Tumor-Specific Antigen Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Tumor-Specific Antigen Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Tumor-Specific Antigen revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Tumor-Specific Antigen revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Agilent Technologies
• Creative Diagnostics
• Go Therapeutics
• Lee Biosolutions
• Bio-Rad
• Biomrieux
• Caris Life Sciences
• Roche
• Abcam
• Merck Group
• PerkinElmer
• OriGene Technologies

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Tumor-Specific Antigen Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Tumor-Specific Antigen Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL TUMOR-SPECIFIC ANTIGEN OVERALL MARKET SIZE

2.1 Global Tumor-Specific Antigen Market Size: 2021 VS 2028
2.2 Global Tumor-Specific Antigen Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Tumor-Specific Antigen Players in Global Market
3.2 Top Global Tumor-Specific Antigen Companies Ranked by Revenue
3.3 Global Tumor-Specific Antigen Revenue by Companies
3.4 Top 3 and Top 5 Tumor-Specific Antigen Companies in Global Market, by Revenue in 2021
3.5 Global Companies Tumor-Specific Antigen Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor-Specific Antigen Players in Global Market
  3.6.1 List of Global Tier 1 Tumor-Specific Antigen Companies
  3.6.2 List of Global Tier 2 and Tier 3 Tumor-Specific Antigen Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Tumor-Specific Antigen Market Size Markets, 2021 & 2028
  4.1.2 Coding Region
  4.1.3 Non-Coding Region
4.2 By Type - Global Tumor-Specific Antigen Revenue & Forecasts
  4.2.1 By Type - Global Tumor-Specific Antigen Revenue, 2017-2022
  4.2.2 By Type - Global Tumor-Specific Antigen Revenue, 2023-2028
  4.2.3 By Type - Global Tumor-Specific Antigen Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Tumor-Specific Antigen Market Size, 2021 & 2028
  5.1.2 Drug Discovery and Development
  5.1.3 Diagnostics
  5.1.4 Clinical and Basic Research
  5.1.5 Others
5.2 By Application - Global Tumor-Specific Antigen Revenue & Forecasts
  5.2.1 By Application - Global Tumor-Specific Antigen Revenue, 2017-2022
  5.2.2 By Application - Global Tumor-Specific Antigen Revenue, 2023-2028
  5.2.3 By Application - Global Tumor-Specific Antigen Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Tumor-Specific Antigen Market Size, 2021 & 2028
6.2 By Region - Global Tumor-Specific Antigen Revenue & Forecasts
  6.2.1 By Region - Global Tumor-Specific Antigen Revenue, 2017-2022
  6.2.2 By Region - Global Tumor-Specific Antigen Revenue, 2023-2028
  6.2.3 By Region - Global Tumor-Specific Antigen Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Tumor-Specific Antigen Revenue, 2017-2028
  6.3.2 US Tumor-Specific Antigen Market Size, 2017-2028
  6.3.3 Canada Tumor-Specific Antigen Market Size, 2017-2028
  6.3.4 Mexico Tumor-Specific Antigen Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Tumor-Specific Antigen Revenue, 2017-2028
  6.4.2 Germany Tumor-Specific Antigen Market Size, 2017-2028
  6.4.3 France Tumor-Specific Antigen Market Size, 2017-2028
  6.4.4 U.K. Tumor-Specific Antigen Market Size, 2017-2028
  6.4.5 Italy Tumor-Specific Antigen Market Size, 2017-2028
  6.4.6 Russia Tumor-Specific Antigen Market Size, 2017-2028
  6.4.7 Nordic Countries Tumor-Specific Antigen Market Size, 2017-2028
  6.4.8 Benelux Tumor-Specific Antigen Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Tumor-Specific Antigen Revenue, 2017-2028
  6.5.2 China Tumor-Specific Antigen Market Size, 2017-2028
  6.5.3 Japan Tumor-Specific Antigen Market Size, 2017-2028
  6.5.4 South Korea Tumor-Specific Antigen Market Size, 2017-2028
  6.5.5 Southeast Asia Tumor-Specific Antigen Market Size, 2017-2028
  6.5.6 India Tumor-Specific Antigen Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Tumor-Specific Antigen Revenue, 2017-2028
  6.6.2 Brazil Tumor-Specific Antigen Market Size, 2017-2028
  6.6.3 Argentina Tumor-Specific Antigen Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Tumor-Specific Antigen Revenue, 2017-2028
  6.7.2 Turkey Tumor-Specific Antigen Market Size, 2017-2028
  6.7.3 Israel Tumor-Specific Antigen Market Size, 2017-2028
  6.7.4 Saudi Arabia Tumor-Specific Antigen Market Size, 2017-2028
  6.7.5 UAE Tumor-Specific Antigen Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Agilent Technologies
  7.1.1 Agilent Technologies Corporate Summary
  7.1.2 Agilent Technologies Business Overview
  7.1.3 Agilent Technologies Tumor-Specific Antigen Major Product Offerings
  7.1.4 Agilent Technologies Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.1.5 Agilent Technologies Key News
7.2 Creative Diagnostics
  7.2.1 Creative Diagnostics Corporate Summary
  7.2.2 Creative Diagnostics Business Overview
  7.2.3 Creative Diagnostics Tumor-Specific Antigen Major Product Offerings
  7.2.4 Creative Diagnostics Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.2.5 Creative Diagnostics Key News
7.3 Go Therapeutics
  7.3.1 Go Therapeutics Corporate Summary
  7.3.2 Go Therapeutics Business Overview
  7.3.3 Go Therapeutics Tumor-Specific Antigen Major Product Offerings
  7.3.4 Go Therapeutics Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.3.5 Go Therapeutics Key News
7.4 Lee Biosolutions
  7.4.1 Lee Biosolutions Corporate Summary
  7.4.2 Lee Biosolutions Business Overview
  7.4.3 Lee Biosolutions Tumor-Specific Antigen Major Product Offerings
  7.4.4 Lee Biosolutions Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.4.5 Lee Biosolutions Key News
7.5 Bio-Rad
  7.5.1 Bio-Rad Corporate Summary
  7.5.2 Bio-Rad Business Overview
  7.5.3 Bio-Rad Tumor-Specific Antigen Major Product Offerings
  7.5.4 Bio-Rad Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.5.5 Bio-Rad Key News
7.6 Biomrieux
  7.6.1 Biomrieux Corporate Summary
  7.6.2 Biomrieux Business Overview
  7.6.3 Biomrieux Tumor-Specific Antigen Major Product Offerings
  7.6.4 Biomrieux Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.6.5 Biomrieux Key News
7.7 Caris Life Sciences
  7.7.1 Caris Life Sciences Corporate Summary
  7.7.2 Caris Life Sciences Business Overview
  7.7.3 Caris Life Sciences Tumor-Specific Antigen Major Product Offerings
  7.7.4 Caris Life Sciences Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.7.5 Caris Life Sciences Key News
7.8 Roche
  7.8.1 Roche Corporate Summary
  7.8.2 Roche Business Overview
  7.8.3 Roche Tumor-Specific Antigen Major Product Offerings
  7.8.4 Roche Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.8.5 Roche Key News
7.9 Abcam
  7.9.1 Abcam Corporate Summary
  7.9.2 Abcam Business Overview
  7.9.3 Abcam Tumor-Specific Antigen Major Product Offerings
  7.9.4 Abcam Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.9.5 Abcam Key News
7.10 Merck Group
  7.10.1 Merck Group Corporate Summary
  7.10.2 Merck Group Business Overview
  7.10.3 Merck Group Tumor-Specific Antigen Major Product Offerings
  7.10.4 Merck Group Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.10.5 Merck Group Key News
7.11 PerkinElmer
  7.11.1 PerkinElmer Corporate Summary
  7.11.2 PerkinElmer Business Overview
  7.11.3 PerkinElmer Tumor-Specific Antigen Major Product Offerings
  7.11.4 PerkinElmer Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.11.5 PerkinElmer Key News
7.12 OriGene Technologies
  7.12.1 OriGene Technologies Corporate Summary
  7.12.2 OriGene Technologies Business Overview
  7.12.3 OriGene Technologies Tumor-Specific Antigen Major Product Offerings
  7.12.4 OriGene Technologies Tumor-Specific Antigen Revenue in Global Market (2017-2022)
  7.12.5 OriGene Technologies Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Tumor-Specific Antigen Market Opportunities & Trends in Global Market
Table 2. Tumor-Specific Antigen Market Drivers in Global Market
Table 3. Tumor-Specific Antigen Market Restraints in Global Market
Table 4. Key Players of Tumor-Specific Antigen in Global Market
Table 5. Top Tumor-Specific Antigen Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Tumor-Specific Antigen Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Tumor-Specific Antigen Revenue Share by Companies, 2017-2022
Table 8. Global Companies Tumor-Specific Antigen Product Type
Table 9. List of Global Tier 1 Tumor-Specific Antigen Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor-Specific Antigen Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Tumor-Specific Antigen Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Tumor-Specific Antigen Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Tumor-Specific Antigen Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Tumor-Specific Antigen Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Tumor-Specific Antigen Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Tumor-Specific Antigen Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Tumor-Specific Antigen Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Tumor-Specific Antigen Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Tumor-Specific Antigen Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Tumor-Specific Antigen Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Tumor-Specific Antigen Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Tumor-Specific Antigen Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Tumor-Specific Antigen Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Tumor-Specific Antigen Revenue, (US$, Mn), 2023-2028
Table 30. Agilent Technologies Corporate Summary
Table 31. Agilent Technologies Tumor-Specific Antigen Product Offerings
Table 32. Agilent Technologies Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 33. Creative Diagnostics Corporate Summary
Table 34. Creative Diagnostics Tumor-Specific Antigen Product Offerings
Table 35. Creative Diagnostics Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 36. Go Therapeutics Corporate Summary
Table 37. Go Therapeutics Tumor-Specific Antigen Product Offerings
Table 38. Go Therapeutics Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 39. Lee Biosolutions Corporate Summary
Table 40. Lee Biosolutions Tumor-Specific Antigen Product Offerings
Table 41. Lee Biosolutions Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 42. Bio-Rad Corporate Summary
Table 43. Bio-Rad Tumor-Specific Antigen Product Offerings
Table 44. Bio-Rad Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 45. Biomrieux Corporate Summary
Table 46. Biomrieux Tumor-Specific Antigen Product Offerings
Table 47. Biomrieux Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 48. Caris Life Sciences Corporate Summary
Table 49. Caris Life Sciences Tumor-Specific Antigen Product Offerings
Table 50. Caris Life Sciences Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 51. Roche Corporate Summary
Table 52. Roche Tumor-Specific Antigen Product Offerings
Table 53. Roche Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 54. Abcam Corporate Summary
Table 55. Abcam Tumor-Specific Antigen Product Offerings
Table 56. Abcam Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 57. Merck Group Corporate Summary
Table 58. Merck Group Tumor-Specific Antigen Product Offerings
Table 59. Merck Group Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 60. PerkinElmer Corporate Summary
Table 61. PerkinElmer Tumor-Specific Antigen Product Offerings
Table 62. PerkinElmer Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)
Table 63. OriGene Technologies Corporate Summary
Table 64. OriGene Technologies Tumor-Specific Antigen Product Offerings
Table 65. OriGene Technologies Tumor-Specific Antigen Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Tumor-Specific Antigen Segment by Type in 2021
Figure 2. Tumor-Specific Antigen Segment by Application in 2021
Figure 3. Global Tumor-Specific Antigen Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Tumor-Specific Antigen Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Tumor-Specific Antigen Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Tumor-Specific Antigen Revenue in 2021
Figure 8. By Type - Global Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 9. By Application - Global Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 10. By Region - Global Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 11. By Country - North America Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 12. US Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 16. Germany Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 17. France Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 24. China Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 28. India Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 30. Brazil Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Tumor-Specific Antigen Revenue Market Share, 2017-2028
Figure 33. Turkey Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Tumor-Specific Antigen Revenue, (US$, Mn), 2017-2028
Figure 37. Agilent Technologies Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Creative Diagnostics Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Go Therapeutics Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Lee Biosolutions Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bio-Rad Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Biomrieux Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Caris Life Sciences Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Roche Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Abcam Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Merck Group Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. PerkinElmer Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. OriGene Technologies Tumor-Specific Antigen Revenue Year Over Year Growth (US$, Mn) & (2017-2022)